Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BXCL501 for Agitation Associated With Schizophrenia And Bipolar Disorder
NCT05658510Phase 3Completed
- Sponsor
- BioXcel Therapeutics, Inc.
- Start
- Nov 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexmedetomidine in agitation (4 arms), sponsored by BioXcel Therapeutics, Inc. Primary endpoints: Positive and Negative Syndrome Scale - Excited Component at 2 hours and Incidence of Serious Adverse Events and Treatment-Emergent Adverse Events at 12 weeks. Started Nov 2022; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
agitation
Beyond the preview
Go deeper on NCT05658510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05658510.